Cartesian Therapeutics (RNAC) Amortization of Deferred Charges (2015 - 2023)
Cartesian Therapeutics (RNAC) reported Amortization of Deferred Charges of -$78000.0 for Q3 2023, down 139.39% year-over-year from $198000.0 in Q3 2022, and down 157.78% quarter-over-quarter from $135000.0 in Q2 2023.
Cartesian Therapeutics (RNAC) Amortization of Deferred Charges (2015 - 2023) Analysis & Trends
Cartesian Therapeutics (RNAC) has 9 years of Amortization of Deferred Charges data on file, last reported at -$78000.0 in Q3 2023.
- Amortization of Deferred Charges for Q3 2023 came in at -$78000.0, down 139.39% year-over-year; the trailing twelve-month figure through Jun 2024 was -$78000.0 (down 108.6% YoY), and the FY2023 annual result was $455000.0, down 52.26% from the prior year.
- Amortization of Deferred Charges retreated to -$78000.0 in Q3 2023 per RNAC's latest filing, from $135000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $398000.0 in Q1 2023 and troughed at -$78000.0 in Q3 2023.
- A 5-year average of $181157.9 and a median of $196000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2021 and 2023: Amortization of Deferred Charges jumped 314.0% in 2021, then tumbled 139.39% in 2023.
- A 5-year view of Amortization of Deferred Charges shows it stood at $64000.0 in 2019, then surged by 234.38% to $214000.0 in 2020, then decreased by 0.93% to $212000.0 in 2021, then fell by 16.98% to $176000.0 in 2022, then slumped by 144.32% to -$78000.0 in 2023.
- Business Quant data shows RNAC's Amortization of Deferred Charges at -$78000.0 in Q3 2023, $135000.0 in Q2 2023, and $398000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -78,000.00 |
| Sep 30, 2023 | -78,000.00 |
| Jun 30, 2023 | 135,000.00 |
| Jun 30, 2023 | 135,000.00 |
| Mar 31, 2023 | 398,000.00 |
| Mar 31, 2023 | 398,000.00 |
| Dec 31, 2022 | 176,000.00 |
| Dec 31, 2022 | 176,000.00 |
| Sep 30, 2022 | 198,000.00 |
| Sep 30, 2022 | 198,000.00 |
| Jun 30, 2022 | 196,000.00 |
| Jun 30, 2022 | 196,000.00 |
| Mar 31, 2022 | 383,000.00 |
| Mar 31, 2022 | 383,000.00 |
| Dec 31, 2021 | 212,000.00 |
| Dec 31, 2021 | 212,000.00 |
| Sep 30, 2021 | 206,000.00 |
| Sep 30, 2021 | 206,000.00 |
| Jun 30, 2021 | 207,000.00 |
| Jun 30, 2021 | 207,000.00 |